ReviewEuropean journal of nuclear medicine and molecular imaging2017
Therapy assessment in multiple myeloma with PET.
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Relationship of Plasma Cell Infiltration Rates withMolecular imaging and radionuclide therapy · 2025Article
- 18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?BMC medical imaging · 2022Article
- CT-derived relationship between low relative muscle mass and bone damage in patients with multiple myeloma undergoing stem cells transplantation.The British journal of radiology · 2022Article
- Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.Annals of hematology · 2021Article
- Comparison between tumour metabolism derived fromQuantitative imaging in medicine and surgery · 2021Article
- Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.European journal of nuclear medicine and molecular imaging · 2019Article
- Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple MyelomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2018Article
- Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combinedEJNMMI research · 2018Article
- Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.European journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma is a plasma cell dyscrasia producing bone lytic lesions. In recent years, a wide spectrum of therapeutic approaches are available to treat the disease: an accurate therapy assessment has, therefore, become of utmost importance. In this field, imaging is becoming a cornerstone, especially in association with clinical parameters. Among imaging procedures, FDG PET/CT is recognized to provide reliable information, achieved in a very safe and fast procedure. The literature has produced very concordant results from different groups assessing the value of FDG PET/CT as a prognostic factor in general and in therapy assessment, but some issues remain regarding a standardization of image interpretation especially in borderline cases. So far, no data regarding nor other imaging compounds and the use of hybrid tomographs PET/MR are available to define therapy assessment in PET.
Indexed as
Identifiers
28573329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.